Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2019 Dec 04



To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Giornale Italiano di Dermatologia e Venereologia 2019 Dec 04

DOI: 10.23736/S0392-0488.19.06371-5


language: English

Ingenol mebutate therapy in erythroplasia of Queyrat: a new approach

Ilaria PROIETTI 1 , Simone MICHELINI 1, Nevena SKROZA 1, Nicoletta BERNARDINI 1, Ersilia TOLINO 1, Alessia ANZALONE 1, Daniela COLAPIETRA 1, Alessandra MAMBRIN 1, Marco DI FRAIA 1, Anna MARCHESIELLO 1, Veronica BALDUZZI 1, Natale PORTA 2, Vincenzo PETROZZA 2, Concetta POTENZA 1

1 Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Bio-Technologies, Fiorini Hospital, Polo Pontino, Sapienza University of Rome, Rome, Italy; 2 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy


BACKGROUND: Erythroplasia of Queyrat (EQ) is a rare squamous cell carcinoma in situ, usually occurring on the glans penis, the prepuce, or the urethral meatus. Therapy is mandatory because it can progress to invasive carcinoma in up to 30% of cases. Treatment options include 5-fluorouracil, curettage, cryotherapy, radiotherapy, laser, partial or total penectomy, and micro surgery, as also with imiquimod and photodynamic therapies.
METHODS: Between 2015 to 2018 we treated five patients, with histologically confirmed EQ, with ingenol mebutate (IM) 0.015% gel applied for 3 days consecutively.
RESULTS: Three patients showed complete response at one year follow up. Two patients showed partial response after two months so they received a second course of therapy with IM. At one year follow up, one of them showed complete response, the other partial response.
CONCLUSIONS: Our experience demonstrated that IM may be considered as an effective and safe treatment option in EQ. IM offers various advantages such as easy and fast application, rapid complete remission, better compliance, few side effects and excellent cosmetical results. The authors call for further exploitation in bigger trials.

KEY WORDS: Queyrat; Ingenol mebutate; Treatment; Glans penis; Bowen

top of page